Verdant PhytoMed (Pty) Ltd Business Plan › Section 14 › Strategic Insight — Big 4 Perspective

Drawing on extensive experience advising pharmaceutical, agricultural, and regulated industry clients across Africa and internationally, we offer the following strategic observations for investors evaluating this opportunity:

14.1 This Is a Pharmaceutical Export Business, Not a Farm

The single most common misconception among investors approaching the South African cannabis sector is the tendency to evaluate these businesses as agricultural operations. This is fundamentally incorrect. Verdant PhytoMed is, in substance, a regulated pharmaceutical export business that happens to use agricultural inputs. The implications of this distinction are profound:

• The primary barrier to entry is not land or capital — it is regulatory licensing

• The primary value driver is not crop yield — it is GMP certification and export market access

• The primary risk is not agricultural — it is regulatory and compliance risk

• The primary competitive advantage is not cost of production — it is quality certification and buyer relationships

14.2 Key Success Factors

1. Regulatory Execution: Companies that treat SAHPRA licensing as a box-ticking exercise will fail. The regulatory process requires a dedicated, experienced team and 12–18 months of intensive engagement. Early engagement with SAHPRA and the establishment of a regulatory affairs function are non-negotiable prerequisites for success.

2. Quality Over Quantity: The global cannabis commodity market is heading toward price compression. Premium pricing and margin protection require EU-GMP certification, batch-to-batch consistency, and full pharmaceutical-grade documentation. Volume alone will not sustain profitability.

3. Export Relationships First: The South African domestic medicinal cannabis market is negligibly small and will remain so for the foreseeable future. Revenue generation is entirely dependent on export contract execution. Investors should validate the strength and enforceability of offtake agreements before committing capital.

4. Capital Discipline: Cannabis infrastructure is capital-intensive and long-dated. The temptation to over-invest in production capacity before securing offtake agreements has been the downfall of numerous cannabis ventures globally. Verdant PhytoMed’s phased capex model, tied to licence milestones and contract execution, is the appropriate approach.

14.3 Investor Due Diligence Checklist

We recommend that prospective investors conduct the following due diligence procedures prior to committing capital:

• Verification of SAHPRA Section 22C licence application status and timeline expectations

• Independent legal opinion on the enforceability of offtake agreements and export permits

• Technical due diligence on greenhouse design and GMP facility specifications by an independent engineering firm

• Financial model audit by an independent accounting firm

• Background checks on all directors and key personnel

• Insurance coverage review for crop, property, key-man, and directors’ and officers’ (D&O) liability

• Environmental and water use licence verification

• B-BBEE scorecard verification by an accredited verification agency

This document contains proprietary and confidential information. Distribution without written consent is prohibited.